Effectiveness of interferon α-2b and ribavirin combination therapy in the treatment of naive chronic hepatitis C patients in clinical practice

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 5, 2004, Pages 425-431

  Shehab, Thomas M ^a,c   Fontana, Robert J ^a   Oberhelman, Kelly ^a   Marrero, Jorge A ^a   Su, Grace L ^a   Lok, Anna S F ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Saint Joseph Mercy Health System   (United States)

Author keywords

alanine aminotransferase; ALT; EBR; end of treatment biochemical response; end of treatment virological response; EVR; HCV; hepatitis C virus; IFN; interferon; SBR; sustained biochemical response; sustained virological response; SVR; TSH

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; ANEMIA; CORRELATION ANALYSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; NEPHROLITHIASIS; NEUTROPENIA; RASH; REVIEW; TIME SERIES ANALYSIS; VIRUS ACTIVATION;

EID: 2342418781     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00018-7     Document Type: Article

References (38)

1. Anonymous. Recommendations from the National Institutes of Health consensus development conference statement management of hepatitis C. 2002. Hepatology. 36:2002;S3-S20
2. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related disease. MMWR. 47:1998;1-40
3. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., Kaslow R.A., Margolis H.S. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 341:1999;556-562
4. Powell D.W. for the Hepatitis C Consensus Development Panel. National Institutes of Health consensus development conference panel statement management of hepatitis C. Hepatology. 26:(suppl 1):1997;2S-10S
5. Wong J.B., McQuillan G.M., McHutchinson J.G., Poynard T. Estimating future hepatitis C morbidity, mortality and costs in the United States. Am J Public Health. 90:2000;1562-1569
6. McHutchison J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi V.K., Goodman Z.D., Ling M.H., Cort S., Albrecht J.K. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 339:1998;1485-1492
7. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., Bain V., Heathcote J., Zeuzem S., Trepo C., Albrecht J. Randomized trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432
8. McHutchison J.G., Manns M., Patel K., Poynard T., Lindsay K.L., Trepo C., Dienstag J., Lee W.M., Mak C., Garaud J.J., Albrecht J.K. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 123:2002;1061-1069
9. Gross C.P., Mallory R., Heiat A., Krumholz H.M. Reporting the recruitment process in clinical trials who are these patients and how did they get there? Ann Intern Med. 137:2002;10-16
10. Manns M.P., McHutchison J.G., Gordon S.C., Rustgi V., Shiffman M., Reindollar R., Goodman Z.D., Koury K., Ling M., Albrecht J.K. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C a randomised trial. Lancet. 358:2001;958-965
11. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Goncales F.L. Jr, Haussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 347:2002;975-982
12. McHutchison J.G. Hepatitis C advances in antiviral therapy what is accepted treatment now? J Gastroenterol Hepatol. 17:2002;431-441
13. Herrine S.K. Approach to the patient with chronic hepatitis C virus infection. Ann Intern Med. 136:2002;747-757
14. Shehab T.M., Sonnad S., Lok A.S.F. Management of hepatitis C patients by primary care physicians in the USA results of a national survey. J Viral Hepatitis. 8:2001;377-383
15. Shehab T.M., Sonnad S.S., Jeffries M., Gunaratnam N., Lok A.S. Current practice patterns of primary care physicians in the management of patients with hepatitis C. Hepatology. 30:1999;794-800
16. Nicklin D.E., Schultz C., Brensinger C.M., Wilson J.P. Current care of hepatitis C patients by primary care physicians in an integrated delivery system. J Am Board Fam Pract. 12:1999;427-435
17. Afdhal N.H., Dieterich D.T., Pockros P.J., Schiff E.R., Shiffman M.L., Sulkowski M.S., Wright T., Younossi Z., Bowers P.J. Epoietin alfa treatment of anemic HCV-infected patients allows for maintenance of ribavirin dose, increases hemoglobin levels and improves quality of life vs. placebo a randomized, double-blind, multicenter study (abstr). Gastroenterology. 124:2003;505A
18. Clark C.H., Ghalib R.H. Hepatitis C role of the advanced practice nurse. AACN Clinical Issues. 10:1999;455-463
19. Allen S.A., Spaulding A.C., Osei A.M., Taylor L.E., Cabral A.M., Rich J.D. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 138:2003;187-190
20. Hirth R.A., Fendrick A.M., Chernew M.E. Specialist and generalist physicians' adoption of antibiotic therapy to eradicate Helicobacter pylori infection. Medical Care. 34:1996;1199-1204
21. Kalra L., Yu G., Perez I., Lakhani A., Donaldson N. Prospective cohort study to determine if trial efficacy of anticoagulation for stroke prevention in a trial fibrillation translates into clinical effectiveness. BMJ. 320:2000;1236-1239
22. Lee J.M., Breslin N.P., Hyde D.K., Buckley M.J., O'Morain C.A. Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther. 13:1999;489-496
23. Spence J.D., Hurley T.C., Spence J.D. Actual practice in hypertension implications for persistence with and effectiveness of therapy. Curr Hypertension Rep. 3:2001;481-487
24. Bauer M.S., Williford W.O., Dawson E.E., Akiskal H.S., Altshuler L., Fye C., Gelenberg A., Glick H., Kinosian B., Sajatovic M. Principles of effectiveness trials and their implementation in VA Cooperative Study #430 "Reducing the efficacy-effectiveness gap in bipolar disorder" J Affective Disorders. 67:2001;61-78
25. Gladstone D.J., Black S.E. Update on intravenous tissue plasminogen activator for acute stroke from clinical trials to clinical practice. Can Med Assoc J. 165:2001;311-317
26. Parker G., Roy K., Wilhelm K., Mitchell P. Assessing the comparative effectiveness of antidepressant therapies a prospective clinical practice study. J Clin Psychiatry. 62:2001;117-125
27. Whisnant J.P. Effectiveness versus efficacy of treatment of hypertension for stroke prevention. Neurology. 46:1996;301-307
28. Fontana R.J., Moyer C.A., Sonnad S.S., Lok A.S.F., Sneed-Pee N., Walsh J., Klein S., Webster S. Comorbidities and quality of life in patients with interferon-refractory chronic hepatitis C. Am J Gastroenterol. 96:2001;170-178
29. Wiley T.E., Brown J., Chan J. Hepatitis C infection in African Americans its natural history and histological progression. Am J Gastroenterol. 97:2002;700-706
30. Howell C., Jeffers L., Hoofnagle J.H. Hepatitis C in African Americans summary of a workshop. Gastroenterology. 119:2000;1385-1396
31. Kimball P., Elswick R.K., Shiffman M. Ethnicity and cytokine production gauge response of patients with hepatitis C to interferon-alpha therapy. J Med Virol. 65:2001;510-516
32. Kinzie J.L., Naylor P.H., Nathani M.G., Peleman R.R., Ehrinpreis M.N., Lybik M., Turner J.R., Janisse J.J., Massanari M., Mutchnick M.G. African Americans with genotype 1 treated with interferon for chronic hepatitis C have a lower end of treatment response than Caucasians. J Viral Hepatitis. 8:2001;264-269
33. McHutchinson J.G. The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa-2b in combination with ribavirin (abstr). Hepatology. 32:2000;247A
34. Hoofnagle J.H. Virahep -C. Hepatology. 36:2002;532-533
35. Jeffers L.J., Cassidy W., Howell C., O'Brien C., Dragutsky M., Fallon M., Daniel S., Dolker M., Sidhu R.K., Harb G.E. Peginterferon alfa-2a (40KD) (Pegasys) in combination with ribavirin in African American and Caucasian patients with HCV genotype 1 an interim report of a comparative, multicenter, efficacy and safety trial (abstr). Hepatology. 36:2002;784A
36. Muir A.J., Bornstein J.D., Killenburg P.G. for the Southeastern Hepatitis Treatment Group. Pegylated interferon alfa-2b and ribavirin for the treatment of chronic hepatitis C infection in African-Americans and non-Hispanic whites. A preliminary report (abstr). Gastroenterology. 122:(suppl):2002;111A
37. Soza A., Everhart J.E., Ghany M.G., Doo E., Heller T., Promrat K., Park Y., Liang T.J., Hoofnagle J.H. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 36:2002;1273-1279
38. Flamm S.L., Eshelman A., Lyons, Levin A., Gordon S.C., Muir A., Sahagun G., Medoff J., Strohecker S., Flora K., Kohagen K., Manka D. Improved medication adherence with cognitive behavioral therapy in patients receiving pegylated interferon alpha 2B (1.5 mcg/kg wk) + ribavirin (800-1400 mg/d) results of a prospective, randomized, controlled, multi-center trial (abstr). Hepatology. 36:2002;592A